Moleculin Biotech (MBRX) Price & Analysis

Compare

1,911 Followers

MBRX Stock Chart & Stats

$4.11

-$0.01(-0.56%)

At close: Jan 08 4:00 PM EST

$4.11

-$0.01(-0.56%)

Day’s Range― - ―

52-Week Range$3.13 - $91.23

Previous CloseN/A

Volume63.82K

Average Volume (3M)2.74M

Market Cap

$12.53M

Enterprise Value-$2.45M

Total Cash (Recent Filing)$6.70M

Total Debt (Recent Filing)$390.00K

Price to Earnings (P/E)―

Beta1.57

Next Earnings

Mar 20, 2026

EPS Estimate

-6.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-17.02

Shares Outstanding3,079,229

10 Day Avg. Volume1,958,319

30 Day Avg. Volume2,738,732

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)24.47

Price to Sales (P/S)0.00

P/FCF Ratio-6.13

Enterprise Value/Market Cap-0.20

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit30.24

Enterprise Value/Ebitda0.06

Forecast

1Y Price Target

$24.33

Price Target Upside491.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Study ResultsThe Phase 1 study confirmed a clean safety profile for WP1066, demonstrated definitive on-target p-STAT3 inhibition, and induced a favorable anti-tumor immune response.

Clinical Trials ProgressMoleculin provided an update on patient recruitment, announcing that 78% of the 45 subjects for the planned interim unblinding have now consented in its ongoing global Phase 3 MIRACLE study of annamycin in relapsed or refractory acute myeloid leukemia (r/r AML).

Partnership ExpansionNewly announced partnership with UNC Chapel Hill highlights annamycin’s broader potential.

Bears Say

Moleculin Biotech News

Moleculin Biotech files to sell 2.61M shares of common stock for holders

16:48 EST Moleculin Biotech (MBRX) files to sell 2.61M shares of common stock for holders Published first on...

17d ago

MBRX

Moleculin Biotech announces results from Phase 1 trial of WP1066

Moleculin Biotech (MBRX) announced results from the Emory University physician-sponsored Phase 1 clinical trial conducted at the Aflac...

24d ago

MBRX

Moleculin Biotech target adjusted to $31 from $300 at Roth Capital

Roth Capital analyst Jonathan Aschoff lowered the firm’s price target on Moleculin Biotech (MBRX) to $31 from $300...

25d ago

MBRX

Moleculin Biotech target adjusted to $22 from $4 at H.C. Wainwright

H.C. Wainwright adjusted the firm’s price target on Moleculin Biotech (MBRX) to $22 from $4 and keeps a...

30d ago

MBRX

Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements

Moleculin Biotech ( ($MBRX) ) just unveiled an update. On May 23, 2025, Moleculin Biotech, Inc. was notified...

3d ago

MBRX

Moleculin Biotech Amends Warrants to Boost Nasdaq Compliance

An update from Moleculin Biotech ( ($MBRX) ) is now available. On December 21, 2025, Moleculin Biotech, Inc....

19d ago

MBRX

Buy Rating for Moleculin Biotech: Promising Progress with WP1066 in Pediatric Brain Tumors

In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Moleculin Biotech, with...

23d ago

MBRX

Moleculin Biotech Reports Positive Phase 1 Trial Results

Moleculin Biotech ( ($MBRX) ) has issued an update. On December 17, 2025, Moleculin Biotech announced promising results...

24d ago

MBRX

Moleculin Biotech Regains Nasdaq Compliance

The latest update is out from Moleculin Biotech ( ($MBRX) ). Moleculin Biotech, Inc. received a deficiency letter...

24d ago

MBRX

Promising Progress in Moleculin Biotech’s Phase 3 MIRACLE Study Boosts Buy Rating

In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Moleculin Biotech, with...

30d ago

MBRX

Moleculin Biotech Enters Inducement Offer Agreements

Moleculin Biotech ( ($MBRX) ) has shared an announcement. On December 9, 2025, Moleculin Biotech, Inc. entered into...

1M ago

MBRX

Moleculin Biotech Updates on MIRACLE Study Progress

Moleculin Biotech ( ($MBRX) ) just unveiled an announcement. On December 9, 2025, Moleculin Biotech announced an update...

1M ago

MBRX

Moleculin Biotech provides update on enrollment for MIRACLE study

Moleculin Biotech (MBRX) provided an update on enrollment from its November report with an increase to 78% of...

1M ago

MBRX

Moleculin Biotech Partners with CIC biomaGUNE for Research

Moleculin Biotech ( ($MBRX) ) has shared an update. On December 8, 2025, Moleculin Biotech announced a research...

1M ago

MBRX

MBRX FAQ

What was Moleculin Biotech’s price range in the past 12 months?

Moleculin Biotech lowest stock price was $3.13 and its highest was $91.22 in the past 12 months.

What is Moleculin Biotech’s market cap?

Moleculin Biotech’s market cap is $12.53M.

When is Moleculin Biotech’s upcoming earnings report date?

Moleculin Biotech’s upcoming earnings report date is Mar 20, 2026 which is in 69 days.

How were Moleculin Biotech’s earnings last quarter?

Moleculin Biotech released its earnings results on Nov 17, 2025. The company reported -$17.015 earnings per share for the quarter, missing the consensus estimate of -$6.583 by -$10.432.

Is Moleculin Biotech overvalued?

According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Moleculin Biotech pay dividends?

Moleculin Biotech does not currently pay dividends.

What is Moleculin Biotech’s EPS estimate?

Moleculin Biotech’s EPS estimate is -6.11.

How many shares outstanding does Moleculin Biotech have?

Moleculin Biotech has 3,079,229 shares outstanding.

What happened to Moleculin Biotech’s price movement after its last earnings report?

Moleculin Biotech reported an EPS of -$17.015 in its last earnings report, missing expectations of -$6.583. Following the earnings report the stock price went down -2.214%.

Which hedge fund is a major shareholder of Moleculin Biotech?

Currently, no hedge funds are holding shares in MBRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Moleculin Biotech

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Moleculin Biotech (MBRX) Earnings & Revenues

Historic Earnings Reports

MBRX Stock 12 Month Forecast

Average Price Target

$24.33

▲(491.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","43":"$43","12.25":"$12.25","22.5":"$22.5","32.75":"$32.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,12.25,22.5,32.75,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.31,5.4399999999999995,7.57,9.7,11.83,13.959999999999999,16.09,18.22,20.349999999999998,22.479999999999997,24.609999999999996,26.74,28.869999999999997,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.31,4.926923076923077,6.543846153846154,8.160769230769231,9.777692307692307,11.394615384615385,13.011538461538462,14.628461538461538,16.245384615384616,17.86230769230769,19.479230769230767,21.096153846153843,22.713076923076922,{"y":24.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.31,4.593846153846154,5.877692307692308,7.161538461538461,8.445384615384615,9.72923076923077,11.013076923076923,12.296923076923077,13.580769230769231,14.864615384615385,16.14846153846154,17.432307692307692,18.716153846153844,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.5,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":37.75,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":32.25,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.63,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >